NCT07093801View on ClinicalTrials.gov

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

May 23, 2029

Study Completion Date

May 23, 2029

Conditions
Metastatic Castration Resistant Prostate Cancer
Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY